Download full-text PDF |
Source |
---|
Bioengineering (Basel)
January 2025
Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, 1001 S McAllister Ave, Tempe, AZ 85281, USA.
Alzheimer's disease (AD) represents a significant global health issue, affecting over 55 million individuals worldwide, with a progressive impact on cognitive and functional abilities. Early detection, particularly of mild cognitive impairment (MCI) as an indicator of potential AD onset, is crucial yet challenging, given the limitations of current diagnostic biomarkers and the need for non-invasive, accessible tools. This study aims to address these gaps by exploring driving performance as a novel, non-invasive biomarker for MCI detection.
View Article and Find Full Text PDFBMJ Open Diabetes Res Care
January 2025
Lady Davis Institute for Medical Research Centre for Clinical Epidemiology, Montreal, Québec, Canada
Objectives: To assess the association between sodium-glucose co-transporter-2 inhibitor (SGLT-2i) use and the risk of incident dementia compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) use among individuals with type 2 diabetes.
Design: A population-based retrospective cohort study.
Setting: The Clinical Practice Research Datalink (CPRD) Aurum database from the UK.
Eur J Trauma Emerg Surg
January 2025
Institute for Research in Operative Medicine (IFOM), Faculty of Health, School of Medicine, Witten/Herdecke University, Ostmerheimer Str. 200, 51109, Cologne, Germany.
Purpose: Our aim was to generate evidence- and consensus-based recommendations for the management of mass casualty incidents (MCIs) based on current evidence. This guideline topic is part of the 2022 update of the German guideline on the treatment of patients with severe/multiple injuries.
Methods: MEDLINE and Embase were systematically searched to August 2021.
Sensors (Basel)
December 2024
Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, 1001 S McAllister Ave, Tempe, AZ 85281, USA.
Alzheimer's disease (AD) and Alzheimer's Related Dementias (ADRD) are projected to affect 50 million people globally in the coming decades. Clinical research suggests that Mild Cognitive Impairment (MCI), a precursor to dementia, offers a critical window of opportunity for lifestyle interventions to delay or prevent the progression of AD/ADRD. Previous research indicates that lifestyle changes, including increased physical exercise, reduced caloric intake, and mentally stimulating activities, can reduce the risk of MCI.
View Article and Find Full Text PDFAlzheimers Dement
January 2025
Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Introduction: Whole genome methylation sequencing (WGMS) in blood identifies differential DNA methylation in persons with late-onset dementia due to Alzheimer's disease (AD) but has not been tested in persons with mild cognitive impairment (MCI).
Methods: We used WGMS to compare DNA methylation levels at 25,244,219 CpG loci in 382 blood samples from 99 persons with MCI, 109 with AD, and 174 who are cognitively unimpaired (CU).
Results: WGMS identified 9756 differentially methylated positions (DMPs) in persons with MCI, including 1743 differentially methylated genes encoding proteins in biological pathways related to synapse organization, dendrite development, and ion transport.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!